At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Dorzolamide-timololdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Topical Aqueous Suppressants on Response to Intravitreal Anti-vascular Endothelial Growth Factor Injections in Age-related Macular Degeneration (AMD), Retinal Vein Occlusions (RVO) or Diabetic Macular Edema (DME).
In Brief
A Phase 2 clinical trial evaluating Dorzolamide-timolol for Wet Macular Degeneration and 3 related conditions. Completed, enrolled 14 participants across 1 site.
Detailed Summary
This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related macular degeneration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
CountriesUnited States
CollaboratorsJ. Arch McNamara Research Fund, Mid Atlantic Retina
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
Primary CompletionSep 2015
First PostedOct 2015
Study CompletionDec 2015
TodayJul 2026
First PostedOct 8, 2015
Enrollment StartFeb 1, 2015
Primary CompletionSep 30, 2015
Study CompletionDec 20, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.7 years ago
Interventions
Dorzolamide-timololdrug
On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration